Ozempic Maker Novo Nordisk Reprimanded by UK Regulators for Payment Disclosure Failures
Ozempic Maker Novo Nordisk Reprimanded by UK Regulators for Payment Disclosure Failures
Novo Nordisk A/S (NYSE:NVO), the maker of the popular obesity drug Ozempic, has been reprimanded by the U.K.'s Prescription Medicines Code of Practice Authority (PMCPA) for failing to disclose fees and expenses paid to individuals and organizations in Britain of approximately 7.8 million pounds (around $10 million) between 2020 and 2022.
諾和諾德製藥（NYSE:NVO）生產的主流幣藥物Ozempic被英國處方藥物行爲規範局（PMCPA）譴責，因未披露2020年至2022年期間向英國個人和組織支付的費用和開支約780萬英鎊（約1000萬美元）
On Friday, the U.K. industry body PMCPA announced that the reprimand followed a voluntary submission by Novo Nordisk regarding these payments.
英國行業機構PMCPA週五宣佈，這次譴責是基於諾和諾德自願提交有關這些支付情況的結果。
Also Read: Joe Biden Suggests Novo Nordisk, Eli Lilly To Lower Prices For Its Popular Obesity Drugs.
還讀：喬·拜登建議Novo Nordisk和Lilly降低其主流幣肥胖症藥物的價格。
The PMCPA stated that the payments involved over 150 bodies, including fees and expenses to health professionals, donations, grants, sponsorships, and other payments to healthcare organizations.
PMCPA稱這些支付涉及150多個機構，包括向衛生專業人士支付費用和支出、捐款、撥款、贊助以及向醫療保健組織支付的其他費用。
Reuters report added that Novo Nordisk explained that these payments were for legitimate activities but were incorrectly categorized in their finance systems due to human error.
路透社的報道還指出，諾和諾德解釋稱這些支付是用於合法的活動，但由於人爲失誤錯誤地分類在他們的財務系統中。
The PMCPA also reported breaches of the Association of the British Pharmaceutical Industry's (ABPI) code of practice by Novartis AG (NYSE:NVS) and Pfizer Inc (NYSE:PFE).
PMCPA還報告了諾華製藥（NYSE:NVS）和輝瑞公司（NYSE:PFE）違反了英國藥品工業協會（ABPI）的行爲準則。
The agency noted that the breaches discredited and reduced confidence in the pharmaceutical industry.
該機構指出，這些違規行爲使藥品行業聲譽受損，削弱了公衆對藥品行業的信懇智能。
In March 2023, Novo Nordisk was suspended as a member of the Association of the British Pharmaceutical Industry (ABPI) for two years due to serious ABPI Code of Practice breaches.
2023年3月，由於嚴重違反英國藥品工業協會行爲準則，諾和諾德被暫停成爲英國藥品工業協會會員兩年。
ABPI's statement linked to a complaint alleging that Novo Nordisk sponsored courses on weight management on LinkedIn for health professionals without clarifying the company's involvement.
ABPI的聲明與一項投訴有關，指控諾和諾德在領英上贊助了有關體重管理課程的課程，但沒有說明公司的參與情況。
Price Action: NVO shares are
價格走勢：NVO股票
- Using Obesity Drugs? Potential Vision Loss Disorder Linked To Novo Nordisk's Ozempic And Wegovy, Study Finds.
- 使用肥胖症藥物？研究發現，諾和諾德的Ozempic和Wegovy可能導致視力喪失疾病。
Photo via Shutterstock
圖片來自shutterstock。
譯文內容由第三人軟體翻譯。